Press Release
Candel Therapeutics (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers
–News Direct–
By Jeremy Golden, Benzinga
Immunotherapy has transformed the way cancer is treated, but just 20% to 40% of patients typically respond to FDA-approved immune checkpoint inhibitor (ICI) treatments.
Poor ICI treatment response has been linked to the tumors ability to disguise antigen presentation and generate an immunosuppressive microenvironment. In addition, most conventional immunotherapies are not designed to educate the patients immune system on how to recognize a variety of tumor antigens and neoantigens.
Amid this landscape, a clinical-stage biopharmaceutical company has developed a new multimodal biological approach that leverages the ability of viral gene constructs to activate cancer-killing mechanisms, exposing multiple tumor antigens to the immune system, resulting in vaccination against the tumor while inhibiting the immunosuppressive tumor microenvironment.
Candel Therapeutics, Inc. (NASDAQ: CADL) is developing a product candidate that is being studied in lung, pancreatic and prostate cancers. Candels most advanced viral immunotherapy candidate, CAN-2409, is an investigational off-the-shelf replication-defective adenovirus designed to induce an individualized, systemic immune response against the patients own tumor.
Part of the companys adenovirus platform, CAN-2409 is injected directly into the tumor or target tissue using a localized injection, akin to the standard approach for vaccination.
CAN-2409's adenoviral construct serves as a vector to transport the HSV-thymidine kinase gene into tumor cells at the site of injection. These tumor cells can then express HSV-thymidine kinase, which converts generic, FDA-approved anti-herpes drugs such as ganciclovir, acyclovir and valacyclovir into a toxic nucleotide analog that blocks DNA synthesis in dividing cells.
Cancer cells exposed to the toxic nucleotide analog in the tumor microenvironment have been observed to undergo immunogenic cell death. Simultaneously, the adenoviral serotype 5 capsid protein elicits a strong pro-inflammatory signal in the tumor microenvironment, creating the optimal conditions to induce a specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad and systemic anti-tumor activity.
CAN-2409 is currently being studied in an open-label, phase 2 clinical trial in non-small cell lung cancer (NSCLC) and in randomized, controlled, blinded phase 2b and phase 3 clinical trials in prostate cancer. The company has recently released very encouraging data for CAN-2409s ability to improve overall survival in non-metastatic pancreatic cancer, with topline overall survival data in non-small cell lung cancer planned for this quarter (Q2 2024) and results from the prostate clinical trials later this year (Q4 2024).
When it comes to NSCLC, the company previously presented data from the phase 2 clinical trial in which patients received two administrations of CAN-2409 plus prodrug. Those patients demonstrated the following:
1) Increased infiltration of CD8+ cytotoxic T cells in the tumor microenvironment, systemic expansion of effector T cells and increased soluble granzyme B levels in peripheral blood;
2) Favorable changes in the trajectory of tumor progression;
3) Decreased tumor size of target lesions in most patients; and
4) Reduced size of uninjected tumor lesions.
The CAN-2409 immunotherapy antitumor strategy aims to increase the number of long survivors beyond 10 to 13 months.
As previous work has shown that progressive disease could be converted into stable disease in most patients with non-small cell lung cancer after CAN-2409 treatment, the hypothesis is that this will translate into improved survival.
When it comes to pancreatic cancer, the company reported notable improvements in patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC) after experimental treatment with CAN-2409. The estimated overall survival rate was 71.4% at 24 months in CAN-2409-treated patients versus only 16.7% in the control arm after chemoradiation.
In 2023, CAN-2409 received Fast Track Designation for both non-small cell lung cancer and pancreatic cancer, a validation from the FDA on its potential. CAN-2409 plus valacyclovir in combination with continued PD-1/PD-L1 agents is being evaluated in an ongoing, open-label phase 2 clinical trial in patients with late-stage NSCLC and an inadequate response to anti-PD(L)-1 therapy. In 2024, CAN-2409 also received Orphan Drug Designation from the FDA for CAN-2409 in borderline resectable pancreatic cancer.
In the upcoming year, Candel plans to announce data readouts for the following:
1) Phase 2 topline overall survival (OS) data for CAN-2409 in NSCLC, expected in Q2 2024;
2) Phase 2 topline data for CAN-2409 in low-to-intermediate-risk, localized, non-metastatic prostate cancer, expected in Q4 2024;
3) Phase 3 topline data for CAN-2409 in localized intermediate/high-risk prostate cancer, expected in Q4 2024.
Featured photo by National Cancer Institute on Unsplash.
Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (HGG). Finally, Candels enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
This article includes certain disclosures that contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, including the timing and availability of additional data, key data readout milestones, including CAN-3110 in HGG; expectations regarding the potential benefits conferred by Fast Track Designation; expectations regarding the therapeutic benefit of its programs, including the potential for its programs to extend patient survival; and expectations regarding cash runway and expenditures. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on managements current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Companys programs; that final data from our pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Companys ability to efficiently discover and develop product candidates; the Companys ability to obtain and maintain regulatory approval of product candidates; the Companys ability to maintain its intellectual property; the implementation of the Companys business model, and strategic plans for the Companys business and product candidates, and other risks identified in the Companys SEC filings, including the Companys most recent Quarterly Report on Form 10-Q filed with the SEC, and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Companys views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
Contact Details
Aljanae Reynolds
+1 617-916-5445
Company Website
View source version on newsdirect.com: https://newsdirect.com/news/candel-therapeutics-nasdaq-cadl-lead-candidate-can-2409-combats-lung-pancreatic-and-prostate-cancers-with-fast-track-designation-for-three-cancers-458506267
Candel Therapeutics
COMTEX_453480918/2655/2024-06-07T08:28:02
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
United States, 29th Apr 2025, – San Francisco, CA — In a world that’s increasingly disconnected from nature, GroundingTime is proud to unveil its latest innovation: the Bamboo Grounding Fitted Sheet | 5X Grounding Power for Better Sleep Groundingtime — a wellness-forward, eco-conscious sleep essential designed to bring the science of grounding into your bedroom, without compromising on style, softness, or sustainability.
Nature-Inspired, Science-Backed
Grounding, also known as earthing, is the practice of connecting your body directly to the Earth’s natural electric charge. Studies suggest that this connection may support better sleep, reduce inflammation, and promote a greater sense of calm and balance.
Our Bamboo Grounding Fitted Sheet is designed to help facilitate this connection — effortlessly. Using a proprietary blend of conductive silver fibers woven into ultra-soft bamboo fabric, the sheet connects via a grounding cord to a grounded outlet, helping your body naturally sync with the Earth’s energy while you sleep.
“We wanted to take The Science Behind Grounding Therapy | How Earth’s Energy Heals – Groundingtime and make it easy, beautiful, and accessible for everyone,” says the GroundingTime product design team. “This sheet is as much about comfort as it is about connection.”
Why Bamboo?
Unlike traditional cotton or synthetic fabrics, bamboo is naturally breathable, hypoallergenic, and antimicrobial. It also happens to be one of the most sustainable resources on the planet.
Each GroundingTime sheet is made from certified organic bamboo sourced from responsibly managed forests, ensuring minimal environmental impact while delivering maximum comfort.
Key Benefits of Bamboo:
Thermoregulating & breathable
Incredibly soft — even after multiple washes
Naturally moisture-wicking and odor-resistant
Hypoallergenic — ideal for sensitive skin
Built-In Multi-Point
Grounding Therapy | 5X Enhanced Grounding Technology – Groundingtime
What sets this sheet apart is its integrated grounding grid of pure silver threads. These threads are seamlessly woven into the fabric, allowing for safe and effective conductivity without sacrificing comfort.
The sheet comes with a grounding cord and adapter that easily connects to a standard grounded outlet, giving you the benefits of grounding while you sleep — with no need to change your habits or routines.
Functional Design That Fits Your Life
The Bamboo Grounding Fitted Sheet is available in multiple sizes, with 15‘’ deep-pocket corners that fit even oversized mattresses. It’s machine-washable, easy to set up, and designed to integrate smoothly with any bedroom aesthetic.
Whether you’re new to grounding or a long-time believer in the benefits, this sheet is a simple yet powerful addition to your wellness routine.
What Customers Are Saying
“I’ve been using the GroundingTime bamboo sheet for just two weeks, and I’ve noticed deeper, more restful sleep. The fabric is unbelievably soft — I honestly don’t want to get out of bed.”
— Laura M., verified buyer
“I’ve struggled with chronic pain in my lower back for years. After sleeping on the GroundingTime bamboo sheet for just a few nights, I woke up with noticeably less stiffness and tension. It’s the first thing I’ve tried that’s made a real difference — naturally.”
— Daniel R., verified buyer
Sustainability at the Core
GroundingTime believes that wellness shouldn’t come at the expense of the planet. That’s why every sheet is packaged in plastic-free, recyclable materials, and a portion of each purchase goes toward reforestation and clean water initiatives.
Availability
The Bamboo Grounding Fitted Sheet is now available exclusively at www.groundingtime.com, with free U.S. shipping.
About GroundingTime
GroundingTime combines scientific research with natural therapy to offer a gentle, nature-based wellness solution for those living with chronic conditions, pain, and sleep challenges. Through grounding technology, we help users reduce stress, improve rest, and support overall health and mind-body balance in everyday life.
Media Contact
Organization: GroundingTime
Contact
Person: Mona
Website:
https://groundingtime.com/
Email:
hello@groundingtime.com
Country:United States
The post GroundingTime Debuts Eco-Friendly Bamboo Grounding Sheet to Redefine Rest appeared first on
Brand News 24.
It is provided by a third-party content
provider. Brand News 24 makes no
warranties or representations in connection with it.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
United States, 29th Apr 2025, – CozyBliss, an innovator in modern home lifestyle products, is excited to announce the launch of its 2025 COOLI PRO Cooling Bedding Collection, a next-generation comfort solution designed to deliver instant cooling and long-lasting comfort throughout the night. The new collection integrates a proprietary woven pattern and Sorona® bio-based fiber technology, offering a superior sleep experience rooted in both innovation and sustainability.
Sleep Cool and Comfortable with Sorona® Fiber
At the heart of the COOLI PRO comforters is advanced Sorona® fiber technology, engineered to enhance breathability and cooling performance. Derived from 37% renewable plant-based materials, Sorona® delivers a 22% increase in loft compared to traditional polyester and improves heat dissipation by 35%. This sustainable fiber also reduces carbon emissions by up to 30% during production. Additionally, the fitted sheet fabrics include 25% GRS-certified recycled PET, further supporting CozyBliss’s commitment to environmental responsibility.
The surface of each comforter boasts a Q-Max value greater than 0.4, enabling an instant cooling effect that can reduce body temperature by 2–5°C. Crafted with precision quilting in both feathered and diamond patterns, the bedding combines tactile cooling with elevated aesthetic appeal. The 3D woven textures not only improve airflow but also provide a sleek, contemporary look that complements modern interior styles.
Stylish, Skin-Friendly, and Safe
The COOLI PRO series is available in sophisticated dual-tone colorways, including Creamy White – Misty White and Meteor Grey – Cool Grey, making it a perfect match for minimalist and modern American home décor.
Every product in the COOLI PRO collection has been independently tested and certified to meet OEKO-TEX® Standard 100, the highest safety standard. This ensures they are free from 138 potentially harmful substances, making them safe for use by all, including infants and those with sensitive skin.
Purchase Information
COOLI Series
Lightweight summer blankets with 100% poly down-alternative filling create a 3D hollow structure for enhanced elasticity and durability. Designed for summer use with excellent abrasion resistance.
COOLI PRO Series
The upgraded COOLI PRO comforter features Sorona® filling with a helical fiber structure for enhanced breathability and support. The reversible design provides both versatility and modern style.
Website: https://www.cozybliss.com/products/lightweight-natural-cooling-comforter?variant=47795869122806
The full collection is available for purchase through the CozyBliss website and Amazon CozyBliss Store.
About CozyBliss
Founded with a vision to redefine modern comfort, CozyBliss is a leading brand in American home living. The company offers an all-season, all-scene product line designed to help consumers effortlessly switch into comfort mode anytime, anywhere. By combining thoughtful design, sustainable materials, and superior craftsmanship, CozyBliss brings lasting coziness to homes around the world.
Media Contact
Organization: CozyBliss
Contact
Person: Media Relations
Website:
https://www.cozybliss.com/
Email:
marketing@cozybliss.com
Country:United States
The post CozyBliss Introduces 2025 COOLI PRO Cooling Comforter Featuring Sorona Technology appeared first on
Brand News 24.
It is provided by a third-party content
provider. Brand News 24 makes no
warranties or representations in connection with it.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Blue Sky Scrubs Celebrates World Environment Day with Commitment to Sustainability and Innovation
United States, 29th Apr 2025, – Austin, TX — As the world comes together to celebrate World Environment Day on June 5, Blue Sky Scrubs is proud to spotlight its ongoing commitment to protecting the planet through thoughtful, sustainable practices. The luxury medical apparel company, known for blending style with functionality, believes that caring for the environment is a natural extension of its mission to care for healthcare professionals.
In honor of World Environment Day on June 5, Blue Sky Scrubs is proud to reaffirm its commitment to protecting the planet through sustainable business practices. As a leader in luxury medical apparel, the company believes that caring for healthcare professionals also means caring for the environment they live and work in.
Blue Sky Scrubs focuses on creating long-lasting products by using premium fabrics and expert craftsmanship, helping reduce the fast-fashion waste cycle. By designing scrubs and accessories that withstand daily wear and maintain their quality over time, the company encourages a more sustainable approach to medical workwear.
In addition, Blue Sky Scrubs minimizes the use of plastic in packaging, supports local and ethical manufacturing, and donates surplus inventory to medical missions and nonprofits, ensuring that unused items serve communities in need rather than ending up in landfills.
“We are inspired every day by healthcare workers who protect and heal,” said Shelby Marquardt, founder of Blue Sky Scrubs. “Our mission is to create products that not only serve them but also help preserve the environment for future generations.”
This World Environment Day, Blue Sky Scrubs invites the healthcare community and its supporters to reflect on the small changes that, together, can make a big difference for the planet.
For more about Blue Sky Scrubs’ sustainability efforts, visit blueskyscrubs.com.
Media Contact
Organization: MFLP
Contact
Person: Suzy Aguilera
Website:
https://blueskyscrubs.com/
Email:
info@blueskyscrubs.com
Contact Number: 18883025837
Country:United States
The post Blue Sky Scrubs Celebrates World Environment Day with Commitment to Sustainability and Innovation appeared first on
Brand News 24.
It is provided by a third-party content
provider. Brand News 24 makes no
warranties or representations in connection with it.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
GroundingTime Debuts Eco-Friendly Bamboo Grounding Sheet to Redefine Rest
CozyBliss Introduces 2025 COOLI PRO Cooling Comforter Featuring Sorona Technology
Blue Sky Scrubs Celebrates World Environment Day with Commitment to Sustainability and Innovation
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
-
Press Release5 days ago
The Illusion of Change — A Bold Philosophical Reflection by Adrian Gabriel Dumitru Challenges the True Nature of Transformation
-
Press Release1 week ago
Premium Resources Confirms High-Grade Copper-Nickel Zone in Botswana, Begins Resource Expansion.
-
Press Release6 days ago
Hybrid Collapse Releases Captivating New Album “Biopolitics”
-
Press Release5 days ago
Raven Keiara named Los Angeles finalist for 2025 August Wilson New Voices Monologue Competition
-
Press Release5 days ago
Champion Window Tinting Announces Cutting-Edge Solutions for Energy Savings and Privacy Enhancement
-
Press Release4 days ago
Cloom Tech Offers OEM Wire Harness Manufacturing Solutions
-
Press Release1 week ago
Sleep Dentistry Brisbane Introduces Safe Laughing Gas Sedation for Stress-Free Visits
-
Press Release7 days ago
MeFold Introduces Foldable, Sustainable Water Bottles to Support Eco-Friendly Lifestyles and On-the-Go Hydration